BIOMAT Database Logo BIOMAT Database Logo

Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) vs CCNU, hpydroxyurea and vincristine in the treatment of malignant glioma. 1979

M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro

UI MeSH Term Description Entries
D008130 Lomustine An alkylating agent of value against both hematologic malignancies and solid tumors. CCNU,Belustine,Cecenu,CeeNU,NSC-79037,NSC 79037,NSC79037
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009607 Nitrosourea Compounds A class of compounds in which the core molecule is R-NO, where R is UREA. Compounds, Nitrosourea
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas

Related Publications

M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
May 1981, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans,
M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man.
May 1973, Cancer,
M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
Treatment of brain tumors with 1-(2 chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
April 1973, Nihon geka hokan. Archiv fur japanische Chirurgie,
M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
1,-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (methyl CCNU) and adriamycin combination therapy.
November 1974, Cancer,
M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
Chloroethyl-cyclohexyl-nitrosourea (CCNU) in the treatment of malignant brain tumors.
September 1973, Journal of neurosurgery,
M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
Nitrosourea combination chemotherapy: 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (methyl-CCNU) and cyclophosphamide.
January 1975, Oncology,
M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea.
January 2004, Report on carcinogens : carcinogen profiles,
M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea.
January 2002, Report on carcinogens : carcinogen profiles,
M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
[Some preliminary observations on chemotherapy of infantile medulloblastomas with vincristine sulfate and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)].
November 1978, Minerva pediatrica,
M Costanza, and M Buechler, and J Munzenreider, and B Emami, and B Mukherji, and W Shucart, and M Scott, and L Nathanson, and R Rudders, and B Stein, and K Post, and A Piro
Alkylation and carbamoylation intermediates from the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-1.
April 1975, Life sciences,
Copied contents to your clipboard!